▶ Mitotane is predicted to decrease the exposure to
corticosteroids (fluticasone).qTheoretical
▶ Mitotane is predicted to markedly decrease the exposure to
crizotinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to dabrafenib.
Avoid.oTheoretical → Also see TABLE 15 p. 1378
is predicted to decrease the exposure to darifenacin.
▶ Mitotane is predicted to decrease the exposure to dasabuvir.
▶ Mitotane is predicted to markedly decrease the exposure to
dasatinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to slightly decrease the exposure to
decreases the exposure to dolutegravir. Adjust dose.
▶ Mitotane is predicted to decrease the exposure to doravirine.
▶ Mitotane is predicted to decrease the exposure to elbasvir.
▶ Mitotane is predicted to decrease the exposure to eliglustat.
▶ Mitotane is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
is predicted to decrease the exposure to encorafenib.
is predicted to decrease the effects of ergotamine.
▶ Mitotane is predicted to decrease the exposure to erlotinib.
Avoid or adjust erlotinib dose, p. 979.rStudy
▶ Mitotane is predicted to decrease the exposure to esketamine.
▶ Mitotane is predicted to decrease the exposure to etravirine.
▶ Mitotane is predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy → Also see
moderately decreases the exposure to exemestane.
▶ Mitotane is predicted to decrease the exposure to fesoterodine.
is predicted to decrease the exposure to fingolimod.
▶ Mitotane is predicted to decrease the exposure to
fosaprepitant. Avoid.oTheoretical
▶ Mitotane is predicted to decrease the exposure to gefitinib.
Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to greatly decrease the concentration of
▶ Mitotane is predicted to decrease the exposure to grazoprevir.
▶ Mitotane is predicted to decrease the concentration of
guanfacine. Adjust guanfacine dose, p. 352.oStudy
▶ Mitotane decreases the concentration of haloperidol. Adjust
▶ Mitotane is predicted to decrease the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 983.rStudy → Also see
▶ Mitotane is predicted to decrease the exposure to idelalisib.
Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to imatinib.
Avoid.oStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to irinotecan.
Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to ivabradine.
▶ Mitotane is predicted to moderately to markedly decrease the
exposure to ivacaftor. Avoid.rStudy
▶ Mitotane is predicted to decrease the exposure to ixazomib.
▶ Mitotane is predicted to decrease the exposure to lapatinib.
is predicted to decrease the exposure to linagliptin.
▶ Mitotane is predicted to decrease the exposure to lomitapide.
Monitor and adjust dose.oTheoretical
▶ Mitotane is predicted to decrease the exposure to lurasidone.
▶ Mitotane is predicted to decrease the exposure to macitentan.
▶ Mitotane is predicted to decrease the exposure to maraviroc.
▶ Mitotane is predicted to decrease the exposure to midazolam.
Monitor and adjust dose.oStudy
▶ Mitotane is predicted to decrease the exposure to midostaurin.
▶ Mitotane is predicted to decrease the exposure to mirtazapine.
▶ Mitotane is predicted to decrease the exposure to montelukast.
BNF 78 Mitotane — Mitotane 1493
▶ Mitotane is predicted to markedly decrease the exposure to
▶ Mitotane is predicted to slightly decrease the exposure to
▶ Mitotane is predicted to decrease the exposure to netupitant.
is predicted to decrease the exposure to nevirapine.
▶ Mitotane is predicted to moderately decrease the exposure to
nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to nitisinone.
▶ Mitotane is predicted to decrease the exposure to olaparib.
Avoid.oTheoretical → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to ombitasvir.
is predicted to decrease the exposure to ondansetron.
▶ Mitotane is predicted to decrease the exposure to opioids
▶ Mitotane is predicted to decrease the exposure to opioids
(buprenorphine). Monitor and adjust dose.oTheoretical
▶ Mitotane decreases the exposure to opioids (methadone).
Monitor and adjust dose.rStudy
▶ Mitotane is predicted to decrease the exposure to opioids
(oxycodone). Monitor and adjust dose.oStudy
▶ Mitotane is predicted to moderately decrease the exposure to
▶ Mitotane is predicted to moderately decrease the exposure to
▶ Mitotane is predicted to decrease the exposure to palbociclib.
▶ Mitotane is predicted to decrease the exposure to paliperidone.
Monitor and adjust dose.rStudy
▶ Mitotane is predicted to decrease the exposure to
panobinostat. Avoid.oTheoretical → Also see TABLE 15
▶ Mitotane is predicted to decrease the exposure to paritaprevir
(with ritonavir and ombitasvir). Avoid.rStudy
▶ Mitotane is predicted to decrease the exposure to pazopanib.
Avoid.rTheoretical → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors
▶ Mitotane is predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors
▶ Mitotane is predicted to moderately to markedly decrease the
exposure to pibrentasvir. Avoid.rStudy
▶ Mitotane is predicted to moderately decrease the exposure to
▶ Mitotane is predicted to decrease the exposure to ponatinib.
▶ Mitotane is predicted to markedly decrease the exposure to
is predicted to decrease the exposure to quetiapine.
▶ Mitotane is predicted to decrease the exposure to ranolazine.
is predicted to decrease the exposure to reboxetine.
▶ Mitotane is predicted to decrease the exposure to regorafenib.
Avoid.oStudy → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to repaglinide.
Monitor blood glucose and adjust dose.oStudy
▶ Mitotane is predicted to markedly decrease the exposure to
▶ Mitotane markedly decreases the exposure to rilpivirine.
▶ Mitotane is predicted to decrease the exposure to risperidone.
▶ Mitotane is predicted to moderately decrease the exposure to
rivaroxaban. Avoid unless patient can be monitored for signs
▶ Mitotane is predicted to decrease the exposure to roflumilast.
▶ Mitotane is predicted to markedly decrease the exposure to
▶ Mitotane is predicted to decrease the exposure to ruxolitinib.
Monitor and adjust dose.oStudy → Also see TABLE 15
▶ Mitotane is predicted to moderately decrease the exposure to
▶ Mitotane is predicted to decrease the concentration of
is predicted to decrease the exposure to solifenacin.
is predicted to decrease the exposure to sorafenib.
Theoretical → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to statins
▶ Mitotane is predicted to decrease the exposure to sunitinib.
Avoid or adjust sunitinib dose, p. 999.oStudy → Also see
▶ Mitotane decreases the concentration of tacrolimus. Monitor
▶ Mitotane is predicted to decrease the exposure to taxanes
(cabazitaxel, paclitaxel). Avoid.rStudy → Also see TABLE 15
▶ Mitotane is predicted to decrease the exposure to taxanes
(docetaxel).rTheoretical → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the concentration of
temsirolimus. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Mitotane decreases the exposure to tetracyclines (doxycycline).
Monitor and adjust dose.oStudy
▶ Mitotane is predicted to decrease the exposure to tezacaftor.
▶ Mitotane is predicted to markedly decrease the exposure to
is predicted to decrease the exposure to tivozanib.
▶ Mitotane is predicted to decrease the exposure to tofacitinib.
▶ Mitotane is predicted to decrease the exposure to tolvaptan.
Use with caution or avoid depending on indication.
▶ Mitotane is predicted to decrease the exposure to toremifene.
▶ Mitotane is predicted to decrease the exposure to trabectedin.
Avoid.rTheoretical → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to vandetanib.
▶ Mitotane is predicted to moderately decrease the exposure to
▶ Mitotane is predicted to decrease the exposure to vemurafenib.
▶ Mitotane is predicted to decrease the exposure to venetoclax.
▶ Mitotane is predicted to decrease the exposure to vinca
alkaloids (vinblastine, vincristine, vindesine).rTheoretical →
▶ Mitotane is predicted to decrease the exposure to vinca
alkaloids (vinflunine). Avoid.rTheoretical → Also see
▶ Mitotane is predicted to decrease the exposure to vinca
▶ Mitotane is predicted to decrease the exposure to vismodegib.
Avoid.oTheoretical → Also see TABLE 15 p. 1378
▶ Mitotane is predicted to decrease the exposure to vortioxetine.
Monitor and adjust dose.oStudy
▶ Mitotane is predicted to decrease the concentration of
▶ Mitotane is predicted to decrease the exposure to zopiclone.
Mitoxantrone → see anthracyclines
Mivacurium → see neuromuscular blocking drugs, non-depolarising
Mizolastine → see antihistamines, non-sedating
1494 Mitotane — Mizolastine BNF 78
Moclobemide → see TABLE 13 p. 1378 (serotonin syndrome)
FOOD AND LIFESTYLE Moclobemide is claimed to cause less
potentiation of the pressor effect of tyramine than the
traditional (irreversible) MAOIs, but patients should avoid
consuming large amounts of tyramine-rich foods (such as
mature cheese, salami, pickled herring, Bovril ®, Oxo ®,
Marmite ® or any similar meat or yeast extract or fermented
soya bean extract, and some beers, lagers or wines).
▶ Moclobemide is predicted to increase the risk of a hypertensive
Theoretical → Also see TABLE 13
▶ Apalutamide is predicted to decrease the exposure to
moclobemide. Avoid or monitor.nStudy
▶ Moclobemide is predicted to increase the risk of severe
Theoretical → Also see TABLE 13 p. 1378
▶ Moclobemide is predicted to increase the exposure to
▶ Moclobemide potentially increases the exposure to clobazam.
▶ Moclobemide is predicted to decrease the efficacy of
▶ Moclobemide is predicted to increase the exposure to
. Avoid or adjust dose—consult product literature.
▶ H2 receptor antagonists (cimetidine) increase the exposure to
moclobemide. Adjust moclobemide dose, p. 362.nStudy
▶ Levodopa increases the risk of side-effects when given with
▶ Moclobemide is predicted to increase the risk of side-effects
when given with linezolid. Avoid and for 14 days after
stopping moclobemide.rTheoretical → Also see TABLE 13
▶ Methylphenidate is predicted to increase the risk of a
hypertensive crisis when given with
▶ Mianserin is predicted to increase the risk of toxicity when
given with moclobemide. Avoid and for 1 week after stopping
mianserin.rTheoretical → Also see TABLE 13 p. 1378
▶ Moclobemide is predicted to increase the effects of monoamineoxidase B inhibitors
▶ Moclobemide is predicted to increase the risk of side-effects
when given with monoamine-oxidase B inhibitors (safinamide).
Avoid and for 1 week after stopping
Theoretical → Also see TABLE 13 p. 1378
▶ Opicapone is predicted to increase the risk of elevated blood
▶ Moclobemide increases the risk of side-effects when given
with phenothiazines (levomepromazine).oStudy
▶ Reboxetine is predicted to increase the risk of a hypertensive
crisis when given with moclobemide. Avoid.rTheoretical
▶ Moclobemide moderately increases the exposure to rizatriptan.
Avoid.oStudy → Also see TABLE 13 p. 1378
▶ Moclobemide moderately increases the exposure to
sumatriptan. Avoid.oStudy → Also see TABLE 13 p. 1378
▶ Moclobemide is predicted to increase the risk of a hypertensive
crisis when given with sympathomimetics, vasoconstrictor
(ephedrine, isometheptene, phenylephrine, pseudoephedrine).
▶ Tricyclic antidepressants are predicted to increase the risk of
severe toxic reaction when given with moclobemide. Avoid.
Theoretical → Also see TABLE 13 p. 1378
▶ Moclobemide slightly increases the exposure to zolmitriptan.
Adjust zolmitriptan dose, p. 482.oStudy → Also see
▶ Antiepileptics (carbamazepine, phenobarbital, primidone) are
predicted to decrease the exposure to modafinil.n Theoretical
▶ Antiepileptics (fosphenytoin, phenytoin) are predicted to
decrease the exposure to modafinil and modafinil is predicted
to increase the concentration of antiepileptics (fosphenytoin,
predicted to increase the exposure to modafinil.nTheoretical
▶ Modafinil is predicted to decrease the exposure to bosutinib.
▶ Cobicistat is predicted to increase the exposure to modafinil.
▶ Modafinil is predicted to decrease the efficacy of combined
hormonal contraceptives. For FSRH guidance, see
Contraceptives, interactions p. 794.rStudy
▶ Modafinil is predicted to decrease the efficacy of desogestrel.
Contraceptives, interactions p. 794.
▶ Modafinil is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Modafinil is predicted to decrease the exposure to elbasvir.
▶ Modafinil is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Modafinil is predicted to decrease the exposure to grazoprevir.
▶ HIV-protease inhibitors are predicted to increase the exposure
▶ Modafinil is predicted to decrease the effects of hormone
replacement therapy.oAnecdotal
▶ Idelalisib is predicted to increase the exposure to modafinil.
▶ Modafinil is predicted to decrease the concentration of
▶ Modafinil is predicted to decrease the efficacy of
levonorgestrel. For FSRH guidance, see Contraceptives,
interactions p. 794.rTheoretical
▶ Macrolides (clarithromycin) are predicted to increase the
exposure to modafinil.nTheoretical
▶ Modafinil is predicted to decrease the efficacy of
norethisterone. For FSRH guidance, see Contraceptives,
interactions p. 794.rAnecdotal
is predicted to decrease the exposure to modafinil.
▶ Modafinil is predicted to decrease the exposure to sofosbuvir.
▶ Modafinil decreases the efficacy of ulipristal. For FSRH
Contraceptives, interactions p. 794.r
▶ Modafinil is predicted to decrease the exposure to velpatasvir.
▶ Modafinil is predicted to decrease the concentration of
voxilaprevir. Avoid.rTheoretical
Mometasone → see corticosteroids
Monoamine-oxidase A and B inhibitors, irreversible → see
TABLE 8 p. 1376 (hypotension), TABLE 13 p. 1378 (serotonin syndrome)
isocarboxazid . phenelzine .tranylcypromine.
FOOD AND LIFESTYLE Potentially life-threatening hypertensive
Bovril ®, Oxo ®, Marmite ® or any similar meat or yeast extract
or fermented soya bean extract, and some beers, lagers or
wines) or foods containing dopa (such as broad bean
pods). Avoid tyramine-rich or dopa-rich food or drinks with,
or for 2 to 3 weeks after stopping, the MAOI.
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the effects of alpha blockers (indoramin).
Avoid.rTheoretical → Also see TABLE 8 p. 1376
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of a hypertensive crisis when
given with amfetamines. Avoid and for 14 days after stopping
the MAOI.rAnecdotal → Also see TABLE 13 p. 1378
▶ Antiepileptics (carbamazepine) are predicted to increase the risk
of severe toxic reaction when given with monoamine-oxidase A
and B inhibitors, irreversible. Avoid and for 14 days after
stopping the MAOI.rTheoretical
BNF 78 Moclobemide — Monoamine-oxidase A and B inhibitors, irreversible 1495
Monoamine-oxidase A and B inhibitors, irreversible (continued)
▶ Antiepileptics (phenobarbital, primidone) are predicted to
increase the effects of monoamine-oxidase A and B inhibitors,
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of antimuscarinic side-effects
antihistamines, non-sedating. Avoid.r
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of antimuscarinic side-effects
antihistamines, sedating. Avoid.r
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of side-effects when given with
. Avoid and for 2 weeks after stopping the MAOI.
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of cardiovascular side-effects
when given with beta2 agonists.oAnecdotal
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of severe hypertension when
given with bupropion. Avoid and for 14 days after stopping the
MAOI.rTheoretical → Also see TABLE 13 p. 1378
▶ Buspirone is predicted to increase the risk of elevated blood
pressure when given with monoamine-oxidase A and B
inhibitors, irreversible. Avoid.rAnecdotal → Also see
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the effects of
doxapram.o ▶ Entacapone is predicted to increase the risk of elevated blood
pressure when given with monoamine-oxidase A and B
inhibitors, irreversible. Avoid.rTheoretical
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to decrease the antihypertensive effects of
. Avoid and for 14 days after stopping the MAOI.
Theoretical → Also see TABLE 8 p. 1376
▶ Levodopa increases the risk of a hypertensive crisis when
given with monoamine-oxidase A and B inhibitors, irreversible.
Avoid and for 14 days after stopping the MAOI.rStudy →
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the risk of side-effects when given with
. Avoid and for 14 days after stopping the MAOI.
Theoretical → Also see TABLE 13 p. 1378
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to alter the antihypertensive effects of methyldopa.
Avoid.rTheoretical → Also see TABLE 8 p. 1376
▶ Methylphenidate is predicted to increase the risk of a
hypertensive crisis when given with monoamine-oxidase A and
B inhibitors, irreversible. Avoid and for 14 days after stopping
▶ Mianserin is predicted to increase the risk of toxicity when
given with monoamine-oxidase A and B inhibitors, irreversible.
Avoid and for 14 days after stopping the MAOI.
Theoretical → Also see TABLE 13 p. 1378
▶ Monoamine-oxidase B inhibitors (rasagiline, selegiline) are
predicted to increase the risk of side-effects when given with
monoamine-oxidase A and B inhibitors, irreversible. Avoid and
for 14 days after stopping the MAOI.rTheoretical → Also
see TABLE 8 p. 1376 → Also see TABLE 13 p. 1378
▶ Monoamine-oxidase B inhibitors (safinamide) are predicted to
No comments:
Post a Comment
اكتب تعليق حول الموضوع